α-Cyano-4-hydroxycinnamic acid is a novel and potent inhibitor of monocarboxylate transporters (MCTs)

AR-C155858 is a novel, selective and potent inhibitor of monocarboxylate transporters MCT1 and MCT2 with Kis of 2.3 nM and 10 nM, respectively.

Valbenazine tosylate (NBI-98854; NBI98854; MT5199; MT-5199; Ingrezza), the tosylate salt of valbenazine, is a VMAT2 (vesicular monoamine transporter 2) inhibitor approved in 2017 by FDA for the treatment of TD/tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts).

BAY-8002 is a novel, potent, selective, and orally bioactive inhibitor of monocarboxylate transporter 1 (MCT1) with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, it displays excellent selectivity against MCT4.

7ACC2 (7-ACC2), an aminocarboxycoumarin derivative, is a novel and potent MCT (Monocarboxylate transporters) inhibitor with anticancer activity.

AZD3965 is a novel, potent and selective MCT1 (monocarboxylate transporter 1) inhibitor with a Ki of 1.6 nM, it showed 6-fold selectivity over MCT2.